Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Privia Health Group, Inc. Market Cap
From what 21 stock analysts predict, the share price for Privia Health Group, Inc. (PRVA) might increase by 23.94% in the next year. This is based on a 12-month average estimation for PRVA. Price targets go from $21 to $30. The majority of stock analysts believe PRVA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
PRVA is a stock in Healthcare which has been forecasted to be worth $26.25 as an average. On the higher end, the forecast price is $30 USD by Andrew Mok from UBS and on the lower end PRVA is forecasted to be $21 by Adam Ron from B of A Securities.
These are the latest 20 analyst ratings of PRVA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Lisa Gill JP Morgan | Overweight | $28 | Maintains | Nov 29, 2024 |
| Andrew Mok Barclays | Equal-Weight | $21 | Maintains | Nov 8, 2024 |
| Jailendra Singh Truist Securities | Buy | $27 | Maintains | Nov 8, 2024 |
| Matthew Gillmor Keybanc | Overweight | $23 | Initiates | Oct 11, 2024 |
| Michael Ha Baird | Outperform | $24 | Maintains | Aug 26, 2024 |
| Sean Dodge RBC Capital | Outperform | $28 | Reiterates | Aug 14, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $20 | Maintains | Jul 9, 2024 |
| Michael Ha Baird | Outperform | $23 | Initiates | May 30, 2024 |
| Andrew Mok Barclays | Equal-Weight | $19 | Maintains | May 20, 2024 |
| Jailendra Singh Truist Securities | Buy | $24 | Maintains | May 15, 2024 |
| Richard Close Canaccord Genuity | Buy | $26 | Maintains | May 10, 2024 |
| Craig Jones Stifel | Buy | $24 | Maintains | May 1, 2024 |
| Daniel Grosslight Citigroup | Buy | $25 | Initiates | Apr 22, 2024 |
| Richard Close Canaccord Genuity | Buy | $37 | Maintains | Mar 19, 2024 |
| Lisa Gill JP Morgan | Overweight | $30 | Maintains | Mar 6, 2024 |
| Andrew Mok Barclays | Equal-Weight | $22 | Initiates | Mar 6, 2024 |
| Andrew Mok UBS | Buy | $29 | Maintains | Mar 1, 2024 |
| Gary Taylor TD Cowen | Outperform | $26 | Maintains | Mar 1, 2024 |
| Jailendra Singh Truist Securities | Buy | $28 | Maintains | Feb 29, 2024 |
| Elizabeth Anderson Evercore ISI Group | Outperform | $25 | Maintains | Feb 28, 2024 |
When did it IPO
2021
Staff Count
1,102
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Parth Mehrotra
Market Cap
$2.54B
In 2023, PRVA generated $1.66B in revenue, which was a increase of 22.19% from the previous year. This can be seen as a signal that PRVA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 04 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investors are comparing Definitive Healthcare Corp. (DH) and Privia Health (PRVA) to determine which stock presents better value opportunities.
Why It Matters - The comparison between Definitive Healthcare and Privia Health highlights potential investment opportunities, guiding value investors in making informed decisions based on relative stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Investors in Medical Info Systems should compare Definitive Healthcare Corp. (DH) and Privia Health (PRVA) to assess which stock currently provides better value.
Why It Matters - The comparison between Definitive Healthcare Corp. and Privia Health highlights potential investment opportunities, guiding value investors toward more promising stock selections.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Privia Health Group, Inc. (NASDAQ: PRVA) will hold its Q3 2024 earnings conference call on November 7, 2024, at 8:00 AM ET, featuring key executives and analysts from major financial firms.
Why It Matters - The Q3 earnings call indicates upcoming financial performance insights for Privia Health, impacting stock valuation and investor sentiment. Analyst participation signals potential market interest.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Privia Health Group, Inc. (Nasdaq: PRVA) announced its financial results for Q3 and the first nine months of 2024, as reported on November 7, 2024.
Why It Matters - Privia Health's financial results can impact stock performance, indicating growth or challenges that affect investor sentiment and future valuations.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Privia Health (PRVA) reported Q3 earnings of $0.03 per share, below the Zacks estimate of $0.06, and down from $0.05 per share year-over-year.
Why It Matters - Privia Health's earnings miss signals weaker performance, potentially leading to reduced investor confidence and stock price volatility.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Privia Health's Q3 2024 financial results are available, highlighting key metrics against Wall Street estimates and year-over-year performance for investors' review.
Why It Matters - Key metrics versus Wall Street estimates and year-ago values indicate Privia Health's performance trajectory, impacting future growth expectations and investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
